Study Links COVID-19 to Reactivation of Dormant Viruses and Long COVID Symptoms
A study published in the journal Nature has shed light on the complex interactions between COVID-19 and dormant viruses within the human body. Researchers evaluated the reactivation of dormant viruses in over 1,100 adults hospitalized with COVID-19, discovering that certain viruses, particularly from the Herpesviridae and Anelloviridae families, were reactivated during illness. The study indicates that nearly 48% of participants experienced viral reactivation, which was notably linked to the severity of their COVID-19 cases and potential long COVID symptoms.
The research team analyzed samples from the Immunophenotyping Assessment in a COVID-19 Cohort (IMPACC) study, focusing on individuals who had not received any COVID-19 vaccinations prior to hospitalization. Participants were categorized based on the severity of their illness, and samples were collected, including blood and nasal swabs, with some data extending up to a year after their hospital admission.
Among the findings, it was noted that reactivation of viruses such as the human alphaherpesvirus (HSV1) and cytomegalovirus occurred approximately 20 days after hospital admission. The researchers found a correlation between the presence of certain reactivated viruses and increased risks of severe outcomes, including death, particularly in patients classified as critical. For instance, those with detectable levels of Epstein-Barr virus (EBV) or cytomegalovirus in their respiratory systems faced higher mortality risks within a year.
The study also highlighted that reactivation of Anelloviridae was associated with severe complications, including shock and ICU admission. The authors, Dr. Esther Melamed and Dr. Cole Maguire, emphasized the significance of their findings, noting that reactivation was common even among previously healthy individuals, indicating a broader impact of COVID-19 than previously understood.
Furthermore, the research explored the relationship between viral reactivation and long COVID symptoms. Participants who reported ongoing fatigue or physical disability were more likely to have active Anelloviridae in their samples during recovery. This marks a significant finding as it links a lesser-known virus family to long COVID for the first time.
While the study provides valuable insights, it also has limitations. The findings are based on a cohort that primarily experienced early strains of SARS-CoV-2 and were unvaccinated, raising questions about the applicability of results to vaccinated populations or those infected with newer variants. Additionally, the study's design and sample collection methods may have influenced the outcomes.
Experts not involved in the study, such as Dr. Arturo Casadevall from Johns Hopkins Medicine, noted that while the implications of these findings are still uncertain, they suggest that viral reactivation could contribute to the inflammatory responses associated with COVID-19 and long COVID. Dr. Jimmy Johannes, a pulmonologist, echoed this sentiment, highlighting the potential for future research to clarify the role of viral reactivation in COVID-19 complications and long-term health outcomes. The authors hope that their findings will pave the way for targeted therapies for these viruses, which currently lack approved treatments.




